OSR Health, Inc. received a Staff Determination Letter from Nasdaq notifying it of the delisting of its common stock and warrants due to failure to maintain the $1.00 minimum bid price requirement under Listing Rule 5550(a)(2). Trading is scheduled to be suspended on August 26, 2026, though a hearing request filed by August 26 may stay the final delisting pending a Panel decision. The company cites extraordinary trading volume of approximately 370 million shares on August 17 and an intraday price high of $0.84 as grounds for appeal. OSR Health operates in the healthcare sector, focusing on biomedical innovations including immuno-oncology, regenerative biologics, and medical device technologies.
